We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+11.35%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$81.6B
AUM Growth
+$7.7B
(+10%)
Cap. Flow
+$798M
Cap. Flow
% of AUM
0.98%
Top 10 Holdings %
Top 10 Hldgs %
23.85%
Holding
3,095
New
53
Increased
1,513
Reduced
1,408
Closed
84
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$65.3M |
| 2 |
Amazon
AMZN
|
+$50M |
| 3 |
Tesla
TSLA
|
+$30.5M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$26.6M |
| 5 |
EPAM Systems
EPAM
|
+$26.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KSU
Kansas City Southern
KSU
|
+$39.1M |
| 2 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
+$31.2M |
| 3 |
XEC
CIMAREX ENERGY CO
XEC
|
+$23.4M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$21.9M |
| 5 |
SBNY
Signature Bank
SBNY
|
+$17.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.54% |
| 2 | Financials | 13.15% |
| 3 | Healthcare | 12.95% |
| 4 | Consumer Discretionary | 12.27% |
| 5 | Industrials | 8.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2626
PureCycle Technologies
PCT
$1.45B
| $373K | ﹤0.01% |
39,000
+10,846
| +39% | +$131K |
|
|
JNCE
2627
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $373K | ﹤0.01% |
44,718
+2,145
| +5% | +$17.7K |
|
2628
ALX Oncology
ALXO
$290M
| $372K | ﹤0.01% |
17,319
-302
| -2% | -$13K |
|
2629
Caesarstone
CSTE
$79.5M
| $372K | ﹤0.01% |
32,788
-50
| -0.2% | -$599 |
|
2630
Precigen
PGEN
$2.59B
| $371K | ﹤0.01% |
100,026
-2,069
| -2% | -$8.9K |
|
2631
Outdoor Holding Co
POWW
$247M
| $368K | ﹤0.01% |
67,578
+3,362
| +5% | +$20.5K |
|
2632
InvenTrust Properties
IVT
$2.59B
| $367K | ﹤0.01% |
+13,459
| New | +$340K |
|
2633
Vital Farms
VITL
$525M
| $367K | ﹤0.01% |
20,336
-445
| -2% | -$7.85K |
|
2634
Kartoon Studios
TOON
$34.9M
| $366K | ﹤0.01% |
34,866
-309
| -0.9% | -$4.04K |
|
2635
NVE Corp
NVEC
$609M
| $365K | ﹤0.01% |
5,339
-86
| -2% | -$5.89K |
|
|
RDUS
2636
DELISTED
Radius Health, Inc.
RDUS
| $365K | ﹤0.01% |
52,744
-1,295
| -2% | -$19K |
|
|
ITIC
2637
Investors Title Co
ITIC
$547M
| $363K | ﹤0.01% |
1,840
-33
| -2% | -$6.85K |
|
2638
CS Disco
LAW
$279M
| $362K | ﹤0.01% |
10,119
-2,103
| -17% | -$93.3K |
|
2639
Crescent Energy
CRGY
$3.82B
| $360K | ﹤0.01% |
+28,426
| New | +$393K |
|
2640
Cue Biopharma
CUE
$114M
| $360K | ﹤0.01% |
1,060
-20
| -2% | -$7.73K |
|
|
ALLK
2641
DELISTED
Allakos
ALLK
| $359K | ﹤0.01% |
36,642
+237
| +0.7% | +$19.4K |
|
2642
Aemetis
AMTX
$124M
| $359K | ﹤0.01% |
29,177
+2,812
| +11% | +$49.7K |
|
2643
Definitive Healthcare
DH
$75.3M
| $359K | ﹤0.01% |
+13,134
| New | +$459K |
|
|
TBCH
2644
Turtle Beach Corp
TBCH
$277M
| $359K | ﹤0.01% |
16,119
-293
| -2% | -$7.91K |
|
2645
GCM Grosvenor
GCMG
$820M
| $358K | ﹤0.01% |
34,129
+3,066
| +10% | +$34.3K |
|
|
KLRS
2646
Kalaris Therapeutics
KLRS
$96.8M
| $358K | ﹤0.01% |
1,204
-22
| -2% | -$10.2K |
|
|
CBAY
2647
DELISTED
Cymabay Therapeutics
CBAY
| $357K | ﹤0.01% |
105,702
-485
| -0.5% | -$1.84K |
|
|
DMTK
2648
DELISTED
DermTech, Inc. Common Stock
DMTK
| $356K | ﹤0.01% |
22,535
-292
| -1% | -$7.01K |
|
2649
Atomera
ATOM
$214M
| $355K | ﹤0.01% |
17,662
-368
| -2% | -$8.64K |
|
2650
Cartesian Therapeutics
RNAC
$268M
| $354K | ﹤0.01% |
3,616
+11
| +0.3% | +$1.18K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2021 Portfolio in Review
As of Q4 2021, RhumbLine Advisers held 3,095 positions worth $81.6B, up 10% from $73.9B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Trading was light in Q4 2021: portfolio turnover was 4.4%. RhumbLine Advisers opened 53 new positions and exited 84, leaving the 3,095-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 24% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2021 buy was Rivian: 125,331 shares worth $13M.
- RhumbLine Advisers added most to Microsoft in Q4 2021, an estimated $65.3M increase.
- RhumbLine Advisers's biggest Q4 2021 reduction was Berkshire Hathaway Class B, cutting an estimated $21.9M.
- RhumbLine Advisers fully exited Kansas City Southern in Q4 2021, selling an estimated $39.1M.
- RhumbLine Advisers's ten largest holdings make up 24% of its $81.6B portfolio in Q4 2021.
- RhumbLine Advisers opened 53 new positions and closed 84 in Q4 2021.
- RhumbLine Advisers's portfolio value rose 10% quarter-over-quarter to $81.6B.
Based on RhumbLine Advisers's 13F filing for Q4 2021, filed 10 Feb 2022.